RÉSUMÉ
Tγδ large granular lymphocyte leukemia (LGLL) is a rare variant of T-cell LGLL (T-LGLL) that has been less investigated as compared with the more frequent Tαß LGLL, particularly in terms of frequency of STAT3 and STAT5b mutations. In this study, we characterized the clinical and biological features of 137 patients affected by Tγδ LGLL; data were retrospectively collected from 1997 to 2020 at 8 referral centers. Neutropenia and anemia were the most relevant clinical features, being present in 54.2% and 49.6% of cases, respectively, including severe neutropenia and anemia in â¼20% of cases each. Among the various treatments, cyclosporine A was shown to provide the best response rates. DNA samples of 97 and 94 cases were available for STAT3 and STAT5b mutation analysis, with 38.1% and 4.2% of cases being mutated, respectively. Clinical and biological features of our series of Tγδ cases were also compared with a recently published Tαß cohort including 129 cases. Though no differences in STAT3 and STAT5b mutational frequency were found, Tγδ cases more frequently presented with neutropenia (P = .0161), anemia (P < .0001), severe anemia (P = .0065), and thrombocytopenia (P = .0187). Moreover, Vδ2- cases displayed higher frequency of symptomatic disease. Overall, Tγδ cases displayed reduced survival with respect to Tαß cases (P = .0017). Although there was no difference in STAT3 mutation frequency, our results showed that Tγδ LGLL represents a subset of T-LGLL characterized by more frequent symptoms and reduced survival as compared with Tαß LGLL.
Sujet(s)
Leucémie à grands lymphocytes granuleux , Neutropénie , Humains , Études rétrospectives , Leucémie à grands lymphocytes granuleux/génétique , Mutation , Neutropénie/génétiqueRÉSUMÉ
Isolated amyloidosis, especially of amyloid light-chain type, is an infrequent disease. Systemic chemotherapy for light-chain amyloidosis isolated to skeletal muscles plays a key role to reduce clonal plasma cells producing aberrant immunoglobulin.
Sujet(s)
Leucémie à grands lymphocytes granuleux/diagnostic , Leucémie à grands lymphocytes granuleux/génétique , Mutation , Protéines tumorales/génétique , Récepteur lymphocytaire T antigène, gamma-delta/génétique , Facteur de transcription STAT-3/génétique , Sujet âgé , Sujet âgé de 80 ans ou plus , Femelle , Humains , Mâle , Adulte d'âge moyenRÉSUMÉ
Aplastic anemia (AA), a hematopoietic disorder characterized by hypocellular bone marrow, is caused by immunologically-mediated hematopoietic stem cell injury. Viral infection is hypothesized as the underlying cause of hepatitis-associated AA, although its mechanism is still unclear. This report describes a case of AA following suspected drug-induced liver injury (DILI). An 18-year-old man developed severe liver dysfunction after taking oral over-the-counter drugs. The patient was diagnosed with suspected DILI based on drug-induced lymphocyte stimulation test and liver biopsy results. Although liver dysfunction improved after a course of steroid pulse therapy and liver supporting therapy, the man gradually developed pancytopenia within 3 months of DILI diagnosis, prompting the diagnosis of AA following DILI. Paroxysmal nocturnal hemoglobinuria-type cells were detected by high-sensitivity flow cytometry. Immunosuppressive therapy with antithymocyte globulin and cyclosporin was administered, with pancytopenia improvement. To the best of our knowledge, this is the first report in the literature with a case of AA following DILI, and we believe it is important for evaluating the pathogenesis of drug-induced and hepatitis-associated AA.
Sujet(s)
Anémie aplasique/étiologie , Lésions hépatiques dues aux substances/complications , Adolescent , Anémie aplasique/traitement médicamenteux , Sérum antilymphocyte/usage thérapeutique , Ciclosporine/usage thérapeutique , Hémoglobinurie paroxystique , Humains , Immunosuppresseurs/usage thérapeutique , MâleSujet(s)
Protocoles de polychimiothérapie antinéoplasique/administration et posologie , Sarcome à cellules de Langerhans/traitement médicamenteux , Tumeurs cutanées/traitement médicamenteux , Sujet âgé , Cyclophosphamide/administration et posologie , Doxorubicine/administration et posologie , Étoposide/administration et posologie , Humains , Sarcome à cellules de Langerhans/anatomopathologie , Mâle , Prednisone/administration et posologie , Tumeurs cutanées/anatomopathologie , Vincristine/administration et posologieRÉSUMÉ
A 62-year-old man presented to the hospital with thrombocytopenia, and splenomegaly was detected. His blood films prepared by natural air drying revealed medium-sized lymphocytes with unevenly distributed large and small villous projections. The cytoplasm was basophilic, nuclei were oval with clumped chromatin, and nucleoli were absent in most cells. Immune phenotypes CD19+, CD20+, CD11c+, FMC7+, IgM+, and Igκ+ were detected. TRAP stain appeared negative, IgH JH chain genes were monoclonally rearranged, and BRAF V600E mutation was not detected. On the basis of these findings, hairy cell leukemia-Japanese variant (HCL-JV) was strongly suspected. The patient was followed up for >4 years without treatment. However, because thrombocytopenia and splenomegaly gradually progressed, splenectomy was performed. Microscopic examination confirmed that the splenic white pulp was atrophic. Moreover, infiltrates comprising small-to-medium-sized atypical lymphocytes with inconspicuous nucleoli were predominantly detected in the congested red pulp. On the basis of these results and immune histochemical findings, the patient was diagnosed with splenic diffuse red pulp small B-cell lymphoma (SDRPL). Here we discussed whether the aforementioned diseases (HCL-JV and SDRPL) are the same; however, further accumulation of cases is essential to draw a definite conclusion.
Sujet(s)
Lymphome B/diagnostic , Splénectomie , Diagnostic différentiel , Humains , Leucémie à tricholeucocytes , Mâle , Adulte d'âge moyen , Rate/anatomopathologie , SplénomégalieRÉSUMÉ
A 68-year-old female with smoldering multiple myeloma (IgG-κ type) was admitted to the hospital owing to general fatigue, fever, and pain in the right leg. On the day following admission, she developed shock, and a blood culture revealed Streptococcus pneumoniae. She was diagnosed with septic shock and invasive pneumococcal disease (IPD). She received antibiotics and intravenous immunoglobulin and improved after several days. She had a history of recurrent IPD and had received the pneumococcal polysaccharide vaccine 23 (PPSV23) 2 years earlier. Therefore, we inquired with the National Institute of Infectious Diseases if the pneumococcal serotype isolated from her present IPD contained PPSV23. The results showed that her serotype was 19F, a serotype present in PPSV23. We administered pneumococcal conjugate vaccine 13 (PCV13) ; however, she was unable to mount high enough opsonophagocytic assay titers against some serotypes, including 19F. We think she was unable to mount effective humoral immune responses to PPSV23 or PCV13 owing to her underlying disease, smoldering myeloma. It should be considered how IPD can be effectively prevented in patients with multiple myeloma.
Sujet(s)
Immunoglobulines par voie veineuse/usage thérapeutique , Infections à pneumocoques/complications , Myélome multiple indolent/complications , Sujet âgé , Femelle , Humains , Infections à pneumocoques/traitement médicamenteux , Infections à pneumocoques/immunologie , Vaccins antipneumococciques/usage thérapeutique , Récidive , Myélome multiple indolent/immunologie , Vaccins conjugués/usage thérapeutiqueRÉSUMÉ
Adult T-cell leukemia/lymphoma (ATLL) is a peripheral T-cell lymphoma caused by human T-cell leukemia virus type 1 infection. Although conjunctival lymphoma is commonly reported with B-cell lymphoma, it rarely occurs in cases of ATLL. A 73-year-old Japanese female patient was admitted to our institution with evidence of abnormal lymphocytes, lymphadenopathy, and lung nodular lesions. Acute type ATLL was diagnosed, and therapy following the mLSG15 protocol was initiated. At the end of the second course, new bone lesions were detected. A modified treatment regimen was scheduled, but was postponed due to the appearance of gastrointestinal symptoms. Close observation resulted in a diagnosis of cytomegalovirus enteritis. One month after the diagnosis, the patient developed pain and discomfort in her left eye, which was determined to be due to a bulbar conjunctival tumor. Pathological findings revealed conjunctival infiltration of ATLL. Mogamulizumab treatment was initiated and was successful in eradicating the conjunctival lesions after the first course. However, at the end of the third course of therapy, pancytopenia was noted. Therefore, mogamulizumab therapy was discontinued, and the patient was on follow-up observation. Although there was no relapse of the conjunctival lesions, the patient died 1 year after the initial diagnosis, following therapy resistance.
Sujet(s)
Tumeurs de la conjonctive/secondaire , Leucémie-lymphome à cellules T de l'adulte/anatomopathologie , Sujet âgé , Anticorps monoclonaux humanisés/usage thérapeutique , Antinéoplasiques/usage thérapeutique , Conjonctive/effets des médicaments et des substances chimiques , Conjonctive/anatomopathologie , Tumeurs de la conjonctive/traitement médicamenteux , Tumeurs de la conjonctive/anatomopathologie , Femelle , Humains , Leucémie-lymphome à cellules T de l'adulte/diagnostic , Leucémie-lymphome à cellules T de l'adulte/traitement médicamenteux , Lymphocytes/effets des médicaments et des substances chimiques , Lymphocytes/anatomopathologieRÉSUMÉ
Large granular lymphocytes (LGLs) are large lymphocytes with azurophilic granules in their cytoplasm. LGLs are either natural killer (NK) cells or T lymphocytes. Expansions of the LGLs in the peripheral blood are seen in various conditions, including three clonal disorders: T-cell LGL (T-LGL) leukemia, chronic lymphoproliferative disorders of NK cells (CLPD-NK), and aggressive NK-cell leukemia (ANKL). However, the monoclonal and polyclonal expansion of LGLs has been associated with many other conditions. The present article describes these LGL disorders, with special emphasis on the clinical features, pathogenesis, and treatments of the three above-mentioned clonal disorders.
Sujet(s)
Cellules tueuses naturelles/anatomopathologie , Leucémie à grands lymphocytes granuleux/anatomopathologie , Leucémie à grands lymphocytes granuleux/thérapie , Adulte , Humains , Leucémie à grands lymphocytes granuleux/diagnostic , Numération des lymphocytes , MâleRÉSUMÉ
We aimed to evaluate care for leukemia and lymphoma patients during their last hospitalization from the perspective of the bereaved family. Questionnaires were sent to the bereaved family members of adult leukemia and lymphoma patients. We used the Care Evaluation Scale (CES) and asked the bereaved family members about care satisfaction and "good death" factors during the patient's last week of life or last admission period. We distributed 177 questionnaires and were able to analyze 103 (58.2%) responses. Compared with the results of a previous study of palliative care units in Japan, the CES scores were significantly lower in 9 out of 10 domains. Assessment of the "good death" components revealed that only 33% of respondents agreed that the patient had been relieved as far as possible of pain and physical distress during the last week of life. Only 21.4% of respondents agreed that the patient had been relieved as far as possible of psychological distress, and 57% of caregivers were not satisfied with the level of care. During the last hospitalizations of leukemia or lymphoma patients, their care was insufficient and a good death was not often achieved. Improvement of end-of-life care for leukemia and lymphoma patients is needed.
Sujet(s)
Famille/psychologie , Leucémies/thérapie , Lymphomes/thérapie , Adulte , Sujet âgé , Femelle , Accompagnement de la fin de la vie/normes , Hospitalisation , Humains , Japon , Mâle , Adulte d'âge moyen , Soins palliatifs/normes , Enquêtes et questionnaires , Soins terminaux/normesRÉSUMÉ
Immunosuppressive therapy has been employed as the initial treatment for acquired chronic pure red cell aplasia (PRCA), such as idiopathic, thymoma-associated, or large granular lymphocyte (LGL) leukaemia-associated PRCA, which is thought to be immune-mediated. To explore the overall long-term outcome following immunosuppression and to identify the risk factors for death in these disorders, we conducted nationwide surveys in Japan 2004 and 2006, and identified a total of 185 patients with acquired chronic PRCA, including 72 idiopathic, 41 thymoma-associated and 14 LGL leukaemia-associated cases of PRCA for whom data was available. The present study evaluated 127 patients with these three subsets of PRCA. The median overall survival has not yet been reached in idiopathic PRCA. The estimated median overall survival times in patients with thymoma-associated and LGL leukaemia-associated PRCA were 142·1 and 147·8 months, respectively. Twenty-two deaths were reported, and the response to induction therapy and relapse of anaemia were found to be associated with death. The major causes of death were infection in seven patients and organ failure in another seven patients. The results suggest that maintenance therapy and the management of infectious complications are crucial for improving the prognosis of chronic PRCA.
Sujet(s)
Immunosuppresseurs/usage thérapeutique , Érythroblastopénie chronique acquise/traitement médicamenteux , Érythroblastopénie chronique acquise/étiologie , Adolescent , Adulte , Sujet âgé , Sujet âgé de 80 ans ou plus , Cause de décès , Maladie chronique , Études de cohortes , Comorbidité , Femelle , Humains , Mâle , Adulte d'âge moyen , Pronostic , Récidive , Érythroblastopénie chronique acquise/épidémiologie , Érythroblastopénie chronique acquise/mortalité , Facteurs de risque , Facteurs temps , Résultat thérapeutique , Jeune adulteRÉSUMÉ
Concurrent chemoradiotherapy has become one of the standard management approaches for newly diagnosed localized nasal natural killer (NK)/T-cell lymphoma (NKTCL). Few data are available on the prognostic biomarkers of NKTCL among patients treated with concurrent chemoradiotherapy. To evaluate the prognostic significance of immunophenotypic biomarkers for patients treated with concurrent chemoradiotherapy, latent membrane protein 1 (LMP1), cutaneous lymphocyte antigen (CLA) and cell origin were examined in samples from 32 patients who were enrolled in the Japan Clinical Oncology Group 0211 trial and treated with concurrent chemoradiotherapy. LMP1 and CLA were positive in 66% (19/29) and 29% (9/31) of the cases examined, respectively. The median follow-up duration was 68 months (range, 61-94). The patients with LMP1-positive tumors showed a better overall survival (OS) than the patients with LMP1-negative tumors (hazard ratio, 0.240; 95% confidence interval [CI], 0.057-1.013; 80% CI, 0.093-0.615; P = 0.035). All five patients with LMP1-negative tumors who experienced disease progression died of lymphoma, and both patients with local failure had LMP1-negative tumors. There was no significant difference in OS according to CLA expression. A total of 27 (84%) cases were of NK-cell origin, two were of αß T-cell origin and three were of γδ T-cell origin. In contrast to those with tumors of NK-cell origin, all five patients with NKTCL of T-cell origin were alive without relapse at the last follow up. Our results indicate that LMP1 expression is a favorable prognostic marker and suggest that a T-cell origin of the tumor may be a favorable prognostic marker for patients with localized NKTCL treated with concurrent chemoradiotherapy.
Sujet(s)
Chimioradiothérapie , Lymphome T-NK extraganglionnaire/diagnostic , Lymphome T-NK extraganglionnaire/thérapie , Adulte , Sujet âgé , Antigènes de différenciation des lymphocytes T/métabolisme , Marqueurs biologiques/métabolisme , Évolution de la maladie , Femelle , Humains , Immunohistochimie , Immunophénotypage , Hybridation in situ , Lymphome T-NK extraganglionnaire/mortalité , Mâle , Glycoprotéines membranaires/métabolisme , Adulte d'âge moyen , Stadification tumorale , Pronostic , Récidive , Résultat thérapeutique , Protéines de la matrice virale/métabolismeRÉSUMÉ
PURPOSE: Extranodal NK/T-cell lymphoma, nasal type (ENKL) is an Epstein-Barr virus (EBV)-associated lymphoma for which a new chemotherapeutic regimen called SMILE (steroid, methotrexate, ifosfamide, L-asparaginase, and etoposide) recently showed promising results. EXPERIMENTAL DESIGN: The amount of EBV-DNA was prospectively measured in whole-blood and plasma samples by real-time quantitative PCR from 26 patients registered in the SMILE phase II study. RESULTS: Before treatment, the EBV-DNA was detected in 22 samples of whole blood with a median number of 3,691 copies/mL (range: 0-1.14 × 10(7)), but 15 samples of plasma with a median of 867 copies/mL (range: 0-1.27 × 10(7)). Results of these 2 measurements of EBV-DNA well correlated (R(2) = 0.994, P < 0.001). The overall response rate to SMILE was significantly higher in patients with less than 10(5) copies/mL of EBV-DNA in whole blood at enrollment (90% vs. 20%, P = 0.007) and in patients with less than 10(4) copies/mL of EBV-DNA in plasma (95% vs. 29%, P = 0.002). The incidence of grade 4 toxicity of SMILE other than leukopenia/neutropenia was significantly higher in patients with 10(5) copies/mL of EBV-DNA or more in whole blood (100% vs. 29%, P = 0.007) than that of others and in patients with 10(4) copies/mL or more in plasma (86% vs. 26%, P = 0.002). CONCLUSIONS: These findings suggest that whole blood is more sensitive for clinical use than plasma. The EBV-DNA amount in whole blood was useful for predicting tumor response, toxicity, and prognosis after SMILE chemotherapy for ENKL.
Sujet(s)
Protocoles de polychimiothérapie antinéoplasique/usage thérapeutique , ADN viral/génétique , Infections à virus Epstein-Barr/traitement médicamenteux , Lymphome T-NK extraganglionnaire/traitement médicamenteux , Adolescent , Adulte , Sujet âgé , Protocoles de polychimiothérapie antinéoplasique/effets indésirables , Asparaginase/administration et posologie , Asparaginase/effets indésirables , ADN viral/sang , Infections à virus Epstein-Barr/sang , Infections à virus Epstein-Barr/virologie , Étoposide/administration et posologie , Étoposide/effets indésirables , Femelle , Herpèsvirus humain de type 4/génétique , Humains , Ifosfamide/administration et posologie , Ifosfamide/effets indésirables , Estimation de Kaplan-Meier , Leucopénie/induit chimiquement , Lymphome T-NK extraganglionnaire/sang , Lymphome T-NK extraganglionnaire/virologie , Mâle , Méthotrexate/administration et posologie , Méthotrexate/effets indésirables , Adulte d'âge moyen , Muqueuse nasale/effets des médicaments et des substances chimiques , Muqueuse nasale/anatomopathologie , Muqueuse nasale/virologie , Neutropénie/induit chimiquement , Pronostic , Études prospectives , Stéroïdes/administration et posologie , Stéroïdes/effets indésirables , Résultat thérapeutique , Jeune adulteRÉSUMÉ
We conducted a retrospective Japan-Korea multicenter study to better elucidate the clinicopathologic features and therapeutic modalities for aggressive natural killer cell leukemia (ANKL). A total of 34 patients were analyzed. The median age of the patients was 40 years. Among the patients in the study, four had a history of Epstein-Barr virus-related disorders. Three types of ANKL cells were categorized according to their morphological features. Leukemic cells were below 20% in both peripheral blood and bone marrow of 11 patients. The clinical characteristics and prognoses of these 11 patients did not differ significantly from those of the others. As an initial therapy, l-asparaginase chemotherapy resulted in a better response. A total of six patients received allogeneic hematopoietic stem cell transplantation (HSCT) and two received autologous HSCT, with all in non-complete remission (CR). After HSCT, four with allogeneic and one with autologous HSCT reached CR. Median survival of all patients was 51 days. Median survival for the patients with and without HSCT were 266 and 36 days, respectively. A total of two patients with allogeneic HSCT were alive and in CR. All patients without HSCT died of ANKL. The use of L-asparaginase was indicated as a factor for longer survival (HR 0.33, 95% confidence interval; 0.13-0.83, P = 0.02). Early diagnosis of ANKL, l-asparaginase-based chemotherapy and allogeneic HSCT might lead to improved patient outcomes.
Sujet(s)
Antinéoplasiques/usage thérapeutique , Asparaginase/usage thérapeutique , Transplantation de cellules souches hématopoïétiques , Cellules tueuses naturelles/anatomopathologie , Leucémie à grands lymphocytes granuleux/traitement médicamenteux , Adolescent , Adulte , Sujet âgé , Antigènes CD , Protocoles de polychimiothérapie antinéoplasique/usage thérapeutique , Association thérapeutique , Femelle , Humains , Leucémie à grands lymphocytes granuleux/thérapie , Mâle , Adulte d'âge moyen , Pronostic , Études rétrospectives , Jeune adulteRÉSUMÉ
PURPOSE: To explore a more effective treatment for newly diagnosed stage IV, relapsed, or refractory extranodal natural killer/T-cell lymphoma, nasal type (ENKL), we conducted a phase II study of the steroid (dexamethasone), methotrexate, ifosfamide, L-asparaginase, and etoposide (SMILE) regimen. PATIENTS AND METHODS: Patients with newly diagnosed stage IV, relapsed, or refractory disease and a performance status of 0 to 2 were eligible. Two cycles of SMILE chemotherapy were administered as the protocol treatment. The primary end point was the overall response rate (ORR) after the protocol treatment. RESULTS: A total of 38 eligible patients were enrolled. The median age was 47 years (range, 16 to 67 years), and the male:female ratio was 21:17. The disease status was newly diagnosed stage IV in 20 patients, first relapse in 14 patients, and primary refractory in four patients. The eligibility was revised to include lymphocyte counts of 500/µL or more because the first two patients died from infections. No treatment-related deaths were observed after the revision. The ORR and complete response rate after two cycles of SMILE chemotherapy were 79% (90% CI, 65% to 89%) and 45%, respectively. In the 28 patients who completed the protocol treatment, 19 underwent hematopoietic stem-cell transplantation. The 1-year overall survival rate was 55% (95% CI, 38% to 69%). Grade 4 neutropenia was observed in 92% of the patients. The most common grade 3 or 4 nonhematologic complication was infection (61%). CONCLUSION: SMILE chemotherapy is an effective treatment for newly diagnosed stage IV, relapsed or refractory ENKL. Myelosuppression and infection during the treatment should be carefully managed.
Sujet(s)
Protocoles de polychimiothérapie antinéoplasique/usage thérapeutique , Lymphome T-NK extraganglionnaire/traitement médicamenteux , Tumeurs du nez/traitement médicamenteux , Adolescent , Adulte , Sujet âgé , Protocoles de polychimiothérapie antinéoplasique/effets indésirables , Asparaginase/administration et posologie , Femelle , Humains , Lymphome T-NK extraganglionnaire/mortalité , Lymphome T-NK extraganglionnaire/anatomopathologie , Mâle , Adulte d'âge moyen , Stadification tumorale , Tumeurs du nez/anatomopathologie , RécidiveRÉSUMÉ
Epstein-Barr virus (EBV)-DNA was prospectively analyzed in plasma and mononuclear cells (MNCs) from peripheral blood in patients with extranodal natural killer (NK)/T-cell lymphoma, nasal type, to evaluate the clinical significance for diagnosis, monitoring the tumor burden, and prognostication. Thirty-three patients were enrolled, and 32 were evaluable. Pretreatment plasma and MNC EBV-DNA was detectable in 14 (range, 50-71 000 copies/mL) and 6 patients (range, 20-780 copies/µg DNA), respectively, and both were well correlated (r = 0.8741, P < .0001). Detectable plasma EBV-DNA was associated with higher clinical stage (P = .02), presence of B symptoms (P = .02), worse performance status (P = .02), and higher serum soluble IL-2 receptor level (P < .0001). Twenty-two patients attained complete response. Plasma EBV-DNA level was significantly higher in nonresponders than in responders (mean, 16,472 vs 2,645 copies/mL; P = .02). Multivariate analysis showed clinical stage (hazard ratio, 9.0; 95% confidence interval, 1.8%-45.0%) and pretreatment plasma EBV-DNA (hazard ratio, 10.6; 95% confidence interval, 1.3%-87.0%) were significant prognostic factors. Three-year overall survival of plasma EBV-DNA positive and negative patients was 42.9% and 94.4%, respectively (P = .0009). Plasma was a preferable sample for this purpose in NK/T-cell lymphoma, nasal type, and EBV-DNA level was a good indicator for response and overall survival.
Sujet(s)
Infections à virus Epstein-Barr , Herpèsvirus humain de type 4/génétique , Lymphome T-NK extraganglionnaire , Tumeurs du nez/virologie , Adolescent , Adulte , Sujet âgé , Sujet âgé de 80 ans ou plus , ADN viral/sang , ADN viral/métabolisme , Infections à virus Epstein-Barr/immunologie , Infections à virus Epstein-Barr/mortalité , Infections à virus Epstein-Barr/virologie , Femelle , Dosage génique/génétique , Humains , Agranulocytes/virologie , Lymphome T-NK extraganglionnaire/immunologie , Lymphome T-NK extraganglionnaire/mortalité , Lymphome T-NK extraganglionnaire/virologie , Mâle , Adulte d'âge moyen , Tumeurs du nez/immunologie , Pronostic , Modèles des risques proportionnels , Études prospectives , Jeune adulteRÉSUMÉ
BACKGROUND: The determination of polymerase chain reaction (PCR) amplification product sizes of the Bcl-2/IgH fusion gene from follicular lymphoma (FL) provides evidence of clonal identity. METHODS: The present study describes detection of Bcl-2/IgH fusion gene clonality utilizing a small, simple microcapillary electrophoretic chip combined with a real-time PCR method. RESULTS: The microcapillary electrophoretic chip system effectively detects size differences among the Bcl-2/IgH fusion gene amplification products of FL from patient samples; something that is not possible using traditional gel electrophoresis. We also describe the potential of this system to utilize formalin-fixed, paraffin-embedded tissue samples sectioned on charged slides. CONCLUSIONS: The simple detection of Bcl-2/IgH fusion gene clonality using a microcapillary electrophoretic chip provides reliable information for monitoring minimal residual disease of FL, and can be an effective tool for use in clinical laboratories.
Sujet(s)
Électrophorèse sur puce/méthodes , Fusion de gènes/génétique , Gènes de chaine lourde d'immunoglobuline/génétique , Gènes bcl-2/génétique , Réaction de polymérisation en chaîne/méthodes , Lignée cellulaire , Femelle , Formaldéhyde/métabolisme , Humains , Mâle , Adulte d'âge moyen , Inclusion en paraffine , Facteurs tempsRÉSUMÉ
The TARGET system is an online database that can be easily accessed by physicians. The registration of one's own chronic myeloid leukemia (CML) patients in the TARGET system makes it possible to share experiences among physicians, and, thus, may facilitate appropriate treatment for patients. Patients were registered in the TARGET system from October 2003 to March 2010 in Japan. A total of 1236 patients from 176 hospitals were registered in Japan. We analyzed data from 639 CML chronic phase patients not receiving prior therapy registered in this system. After 90 months follow-up, high survival rates were demonstrated for imatinib-treated newly diagnosed CML patients, with event-free survival (EFS), progression-free survival (PFS), and overall survival (OS) rates of 79.1, 94.8, and 95.1%, respectively. A landmark analysis of 296 patients who showed a complete cytogenetic response (CCyR) at 12 months after the initiation of imatinib treatment revealed that, at 90 months, 99% of patients (95% CI, 98-100) had not progressed to accelerated phase (AP) or blastic crisis (BC). The patients showing a CCyR and a reduction of at least 3log levels of BCR-ABL transcripts after 18 months of treatment had an estimated survival rate without CML progression of 100% at 84 months. The probability of achieving undetectable BCR-ABL in patients by 72 months with an major molecular response (MMR) at 12 months was 86.5%, compared with 64.7% for those without an MMR (p < 0.0001). There were no new safety issues. In summary, based on this 7-year TARGET analysis, imatinib showed a continual clinical benefit as first-line therapy for newly diagnosed CML. The TARGET system may represent a more practical and general feature compared with the IRIS study.
Sujet(s)
Systèmes de signalement des effets indésirables des médicaments , Bases de données factuelles , Leucémie myéloïde chronique BCR-ABL positive/traitement médicamenteux , Pipérazines/effets indésirables , Pipérazines/usage thérapeutique , Pyrimidines/effets indésirables , Pyrimidines/usage thérapeutique , Adolescent , Adulte , Sujet âgé , Sujet âgé de 80 ans ou plus , Antinéoplasiques/effets indésirables , Antinéoplasiques/usage thérapeutique , Benzamides , Études de suivi , Humains , Mésilate d'imatinib , Internet , Leucémie myéloïde chronique BCR-ABL positive/diagnostic , Mâle , Adulte d'âge moyen , Traitement néoadjuvant , Systèmes en direct , Enregistrements , Facteurs temps , Jeune adulteRÉSUMÉ
Splenic marginal zone lymphoma (SP-MZL) is a rare low-grade B-cell neoplasm that often shows leukemic manifestation. Less than 20% of cases of SP-MZL express CD5. We analyzed 11 cases of CD5-positive SP-MZL with leukemic manifestation. The clinical characteristics of these cases did not differ from those of CD5-negative SP-MZL. Flow cytometry revealed positive results as follows : CD3, 0/9 ; CD5, 11/11 ; CD10, 0/11 ; CD11c, 4/10, CD13, 5/11 ; CD19, 11/11 ; CD20, 10/11 ; CD21, 4/4 ; CD22, 7/7 ; CD23, 5/10 ; CD25, 8/11 ; FMC7, 5/7 ; κ type 6/9, and λ type 2/9. All 3 cases with monoclonal γ-globulinemia expressed CD13. Resected spleen exhibited a proliferation of neoplastic cells in white pulp in all 8 splenectomy patients and a marginal pattern was detected in 5 patients. Only 2 cases showed involvement of red pulp. Immunohistochemistry showed that the lymphoma cells were positive for CD5, CD20, and BCL-2 and negative for CD3, CD10, cyclin D1, BCL-6, and MUM-1 in all 11 cases. These results suggest that CD5-positive SP-MZL differs from B-cell chronic lymphocytic leukemia, that CD13 expression is found in about half of CD5-positive SP-MZL cases, and that CD5-positive SP-MZL may be related to memory B-cell neoplasm or plasma cell differentiation.